LAB (Standard BioTools Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LAB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Michael Egholm | President & CEO | F | — | — |
| 2026-08-24 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2026-08-24 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2026-08-04 | Michael Egholm | President & CEO | F | — | — |
| 2026-07-27 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2026-06-23 | Sean Mackay | SVP & Chief Business Officer | A | — | — |
| 2026-06-23 | KATHY L HIBBS | Director | A | — | — |
| 2026-06-23 | Troy Cox | Director | A | — | — |
| 2026-06-23 | Thomas D. Carey | Director | A | — | — |
| 2026-06-23 | Frank Witney | Director | A | — | — |
| 2026-06-23 | Eli Casdin | Director | A | — | — |
| 2026-06-23 | FENEL M ELOI | Director | A | — | — |
| 2026-05-22 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2026-05-22 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2026-05-22 | Michael Egholm | President & CEO | F | — | — |
| 2026-04-08 | Sean Mackay | SVP & Chief Business Officer | A | — | — |
| 2026-04-08 | Michael Egholm | President & CEO | MIXED | — | — |
| 2026-04-08 | Hanjoon Alex Kim | Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | Troy Cox | Director | A | — | — |
| 2026-03-02 | Thomas D. Carey | Director | A | — | — |
| 2026-03-02 | Eli Casdin | Director | A | — | — |
| 2026-02-24 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2026-02-24 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2026-02-24 | Michael Egholm | President & CEO | F | — | — |
| 2025-12-04 | Casdin Partners Master Fund, L.P. | Director | Buy | — | — |
| 2025-11-26 | Casdin Capital, LLC | Director | Buy | — | — |
| 2025-11-24 | Michael Egholm | President & CEO | F | — | — |
| 2025-11-24 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2025-11-24 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2025-11-20 | Casdin Partners Master Fund, L.P. | Director | Buy | — | — |
| 2025-11-17 | Eli Casdin | Director | Buy | — | — |
| 2025-11-12 | Casdin Private Growth Equity Fund II GP, LLC | Director | Buy | — | — |
| 2025-09-11 | Casdin Private Growth Equity Fund II GP, LLC | Director | Buy | — | — |
| 2025-09-05 | Eli Casdin | Director | Buy | — | — |
| 2025-08-26 | Casdin Private Growth Equity Fund II GP, LLC | Director | Buy | — | — |
| 2025-08-22 | Michael Egholm | President & CEO | F | — | — |
| 2025-08-22 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2025-08-22 | Hanjoon Alex Kim | Chief Financial Officer | F | — | — |
| 2025-08-15 | Casdin Private Growth Equity Fund, L.P. | Director | Buy | — | — |
| 2025-08-05 | Hanjoon Alex Kim | Chief Financial Officer | A | — | — |
| 2025-08-05 | Michael Egholm | President & CEO | A | — | — |
| 2025-07-30 | Troy Cox | Director | — | — | — |
| 2025-06-24 | Frank Witney | Director | A | — | — |
| 2025-06-24 | KATHY L HIBBS | Director | A | — | — |
| 2025-06-24 | Troy Cox | Director | A | — | — |
| 2025-06-24 | FENEL M ELOI | Director | A | — | — |
| 2025-06-24 | Thomas D. Carey | Director | A | — | — |
| 2025-06-24 | Eli Casdin | Director | A | — | — |
| 2025-05-30 | Sean Mackay | SVP & Chief Business Officer | F | — | — |
| 2025-05-30 | Michael Egholm | President & CEO | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 74,851,062 | — |
| — | Director | 64,576,062 | — |
| — | Director | 56,557,253 | — |
| — | Director | 16,840,699 | — |
| — | Director | 16,746,107 | — |
| — | Director | 16,721,069 | — |
| — | 10%+ Owner | 11,189,663 | — |
| — | 10%+ Owner | 8,467,920 | — |
| — | President & CEO | 6,137,704 | — |
| — | Director | 5,797,388 | — |
| — | Director | 5,645,281 | — |
| — | Director | 2,847,775 | — |
| — | Chief Financial Officer | 2,534,859 | — |
| — | SVP & Chief Business Officer | 1,480,823 | — |
| — | Director | 475,702 | — |
| — | SVP & Chief Financial Officer | 421,608 | — |
| — | Director | 344,456 | — |
| — | Director | 335,299 | — |
| — | Director | 314,203 | — |
| — | Chief Financial Officer | 295,260 | — |
| — | Director | 236,836 | — |
| — | Director | 126,844 | — |
| — | Director | 104,791 | — |
| — | Director | 104,111 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LAB quote page; the site-wide leaderboard is on the insider transactions hub.